Eli Lilly (LLY) said Wednesday its Surmount-5 phase 3b clinical study showed that Zepbound provided a 47% "greater relative weight loss" in comparison to Novo Nordisk's (NVO) Wegovy.
Zepbound, Eli Lilly's weight-loss drug, resulted in a "superior" weight reduction of 20.2% against Wegovy's 13.7%, the company added.
Eli Lilly's stock rose 2.3% in recent Wednesday premarket activity, while Novo Nordisk's shares were little changed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。